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Background: Vaccines are specific medicines  characterized by two  country-specific  market  access pro-
cesses: (1) a  recommendation by  National  Immunization Technical  Advisory  Group (NITAG),  and (2)  a
funding  policy  decision.
Objectives:  The objective  of this study  was to compare  and  analyze  NITAGs  of 13  developed  countries by
describing vaccination  committees’ bodies  and working  processes.
Methods: Information about NITAGs bodies and working processes was searched from official  sources
from  June 2011 to November 2012.  Retrieved information was completed from relevant articles identified
through  a  systematic  literature  review  and by  information provided  by  direct contact with  NITAGs  or
parent  organizations.  An  expert  panel  was also  conducted  to discuss,  validate,  and provide  additional
input on obtained  results.
Results:  While complete information,  defined  as  100%, was retrieved  only for  the UK,  at least 80%  of  data
was retrieved  for  9 countries  out  of the  13  selected  countries.  Terms  of references  were  identified  in 7
countries,  and the  main mission  for  all NITAGs was to provide advice for  National immunization  programs.
However,  these  terms  of references  did  not  fully  encompass  all  the  actual missions of the NITAGs.  Decision
analysis  frameworks were identified for  10 out  of the  13, and  all  NITAGs  considered  at least four  criteria
for  decision-making:  disease burden, efficacy/effectiveness,  safety  and  cost-effectiveness.  Advices  were
published by most NITAGs,  but  few NITAGs published  meeting agendas  and  minutes. Only the United
States had  open  meetings.
Conclusions:  This  study  supports  previous  findings about  the  disparities in NITAGs  processes which  could
potentially  explain the  disparity in access to vaccinations  and  immunization  programs  across Europe.
With  NITAGs recommendations  being used by  policy  decision  makers for  implementation  and funding of
vaccine programs, guidances  should  be  well-informed and transparent to ensure  National Immunization
Programs’  (NIP)  credibility  among the  public and  health care  professionals.
©  2014  The Authors.  Published by Elsevier  Ltd. This is an open  access article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Vaccines follow country-specific market access paths that
differ from traditional registration processes. Vaccines’ market
∗ Corresponding author. Tel.: +33 176704790.
E-mail address: mto@creativ-ceutical.com (M.  Toumi).
access processes are characterized first by the development of
recommendations, and are followed by the executive policy-
decision, which includes funding and which is usually based on
the recommendations.
Expert committees, referred as National Immunization Tech-
nical Advisory Group (NITAG), are in charge of developing
recommendations that are ultimately used by policy-makers to
make evidence-based decisions on immunization-related policies
http://dx.doi.org/10.1016/j.vaccine.2014.09.023
0264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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and programs, such as the inclusion of the new vaccine in the
national immunization program (NIP) [1].
NITAGS are country- specific, thus varying greatly from one
country to another. Indeed, Lopalco et al. concluded in  their
study that NITAGs’ policy, including analysis framework and deci-
sions processes, were heterogeneous across European Union (EU)
member states [2]. Piso et al. performed a  Delphi panel of 14
immunization experts and drew similar conclusions about the
heterogeneity of decision-making criteria and processes within
European NITAGs [3].
Immunization policy development processes were also stud-
ied Bryson et al. who presented the results of a  global survey
performed in 2008 with the World Health Organization (WHO)
[4]. Duclos et al. performed an update of the same global survey,
reporting impressive progress in  NITAGs establishment and per-
formance and proposing general guidelines for the NITAGs [5,6].
More recently, a collaborative project, Vaccine European New Inte-
grated Collaboration Effort II  (VENICE II), involving 29 EU countries,
was implemented to  collect and share information on immuniza-
tion programs through a network of professionals to improve the
overall performance of the immunization systems [7].
While Duclos and Piso’s work provided valuable input on
NITAGs processes, there is still need for up-to-date informa-
tion about NITAGs’ policies and recommendations in developed
countries. Indeed, understanding vaccination recommendation
processes is crucial for health policy decision makers, public
health specialists, and civil society. Furthermore, a  comparison
between several NITAGs would allow the identification of both
good practices and shortcomings, and thus pinpoint areas in need of
improvement. Therefore, the objective of this study was to compare
and analyze NITAGs of a selected number of developed countries by
describing vaccination committees’ bodies and working processes.
The comparison aimed to  cover all aspects of NITAGs’ policy such as
reporting, terms of reference, composition, meeting organization,
decision analysis framework, and communication.
2. Methodology
The study was conducted from June 2011 to  November 2012
in 13 countries: Australia, Belgium, Canada, France, Germany,
Hungary, Italy, the Netherlands, Spain, Sweden, Switzerland, the
United Kingdom (UK) and the United States (US). Specific European
countries were selected to provide a  reasonable representation of
developed countries and to  reflect a  variety of health care organi-
zations and funding mechanisms. Three non-European countries,
Australia, Canada, and the US, were selected because of their long
history of NITAG practice and the quality and transparency of their
decision processes [4,6].
2.1. Data extraction
Twenty-five relevant items, based on Duclos et al. work, were
selected to compare NITAGs’ processes in  the selected countries.
Piso et al. article was used to  establish a  list  of relevant criteria
used for analytical framework) [6,8] (Table 1). Data was extracted
from the following three types of sources:
-  Source 1: Official sources defined as NITAGs’ websites, or when
unavailable, those of the relevant parent organizations plus
NITAG resource center [9].
- Source 2: Articles identified through a  systematic literature
review that was performed using the same search strategy
and databases (OVID Medline and Global Health) as Bryson
et al. [4] (Appendix 1). An additional, ad-hoc search was  also
performed for relevant article on the International Society for
Table 1
List of data searched for each NITAG.
List of 25  relevant items searched for each selected country’s NITAG
Name of the NITAG
NITAG’s website/official source
Role/missions of NITAG stated on the website/official source
Name of NITAG’s parent organization
Identification of the stakeholders (non-core members) involved in NITAG’s
meetings
Role of the stakeholders involved during the meetings
Number of NITAG’s core members
Name of NITAG’s core members
Profile composition of NITAG’s core members
Are the core members full time employees of the  NITAG?
Selection process of chairman/other core members
Duration of appointment for core members
Are  the core members remunerated?
Do core members declare conflicts of interest?
Number of NITAG’s meetings per year
Length of NITAG’s meetings
Do subcommittees exist within the NITAG?
Are  NITAG’s meetings open to  public?
Are the NITAG’s meeting agendas published before the meetings?
Are the NITAG’s meeting minutes published after the meetings?
Are  the NITAG’s recommendations published after the meetings?
Are the NITAG’s recommendations published through evaluation reports?
What is the timeline to  get the NITAG’s recommendations publicly
available?
Do the NITAG possess analytical frameworks for decision-making?
Criteria  used for analytical framework
Pharmacoeconomics and Outcomes Research abstracts database
and Google scholar.
- Source 3: Direct contact (primary research) with the NITAGs or
their parent organizations via interviews or questionnaires.
Data were searched through hierarchically ordered sources
(source 1,  then 2 and last 3). The same information found in several
sources was reported as retrieved from the first source.
2.2. Data validation and review by the immunization expert panel
Retrieved information was reviewed by an international immu-
nization expert panel composed of 8 members from France,
Germany, Hungary, Italy, Spain, the UK and the US. All experts
were familiar with vaccine evaluation and NITAGs. There were four
experts were current or former members of NITAGs, two public
health specialists, two health economists, among which a  patients’
representative from European Patients Forum. The immunization
expert panel was convened for a  one-day meeting and provided
complementary information and clarifications in order to validate
the overall study findings and provided context and details sur-
rounding various NITAG’s processes.
2.3. Analysis
Retrieved information analysis was  performed using usual
descriptive statistics, i.e. proportions (Table 2).
3. Results
3.1. Source identification and data collection
Via official sources (Source 1), NITAGs’ websites or parent orga-
nization websites were identified for all selected countries except
Italy [10–21] (Table 2).
A  total of 1658 articles were identified through the litera-
ture review, and 281 duplicates and 1352 articles were excluded
through titles and abstracts review. Thus, 25 studies meeting the
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Table 2
Overview of NITAG’s official sources and of the proportion of information retrieved by source.
Name of NITAG Official Sources* ,+ Proportion of data retrieved by  source
Secondary Research Primary Research Not found
Source 1‡ Source 2‡ Source 3‡
European Countries
Belgium Standing Working Group on  Vaccination (Groupe de
travail permanent Vaccination-Permanente werkgroep
Vaccinatie)
www.health.belgium.be 40% 4% 40%  16%
France  Technical Vaccination Committee (Comité technique des
vaccinations;  CTV)
www.hcsp.fr 46% – 46% 8%
Germany  The German Standing Vaccination Committee (Ständigen
Impfkommission; STIKO)
www.rki.de 96% – –  4%
Hungary  National Center for Epidemiology Committee (Országos
Epidemiológiai Központ; OEK)
www.oek.hu 8% 4% 56% 32%
Italy  National Vaccines Commission (Nazionale Vaccini
Commissione; CNV)
Not found¥ 16% 4% 80%
The  Netherlands Committee on the National Vaccination Program
(Commissie Rijksvaccinatieprogramma; RVP)
www.gezondheidsraad.nl 32% 4% 52% 12%
Spain  Working Group on Vaccines (Ponencia del Programa y
Registro de Vacunaciones i.e. Ponencia de Vacunas)
www.msps.es 44% 4% –  52%
Sweden  National Board of Health and Welfare Expert
Committees (SocialStyrelsen)
www.socialstyrelsen.se 16% 8% 56% 20%
Switzerland The Federal Vaccination Commission (Commission
fédérale pour les vaccinations – Commissione federale per
le vaccinazioni – Eidgenössische Kommission für
Impffragen;  CFV)
www.bag.admin.ch 44% 44% –  12%
UK  The Joint Committee on Vaccination and Immunization
(JCVI)
www.gov.uk/government/organisations/department-of-health 100% – –  0%
Non-European countries
Australia Australian Technical Advisory Group on  Immunization
(ATAGI)
www.health.gov.au 40% 36% –  24%
Canada  The National Advisory Committee on Immunization
(NACI)
www.phac-aspc.gc.ca/naci-ccni 32% 52% –  16%
US¤ The Advisory Committee on  Immunization Practices
(ACIP)
www.cdc.gov 96% – –  4%
* Websites of NITAGs, or, when not available, those of the relevant parent organization.
+ Other Source: NITAG Resource Center [9].
‡ Source 1: Websites of NITAGs or the relevant parent organization; Source 2: systematic literature review; Source 3: direct contact (primary research) with the NITAGs or their parent organizations.
¥ No official website, however the National Plan of Vaccination (Nazionale Prevenzione Vaccinale) 2012–2014 was  available [33].
§ The National Board of Health and Welfare does not have a standing vaccine committee, as such  ‘Vaccine committees’ are founded on  an ad-hoc basis, as per primary research.
¤ Smith et al article “The structure, role, and procedures of the U.S. Advisory Committee on  Immunization Practices (ACIP)” (Vaccine 2010; [30]) was available on CDC’s website, thus considered as source 1.
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inclusion criteria were used as a  secondary source to supplement
the information retrieved through official websites.
Finally, primary research information was obtained for Belgium,
Hungary, the Netherlands and Sweden to  complete information not
available from Sources 1 and 2.
3.2.  Overview of retrieved information
Complete information, defined as 100% (i.e. 25 items retrieved
on 25), was retrieved only for the UK. The proportion of unfound
data ranged from 0% in UK to  80% in Italy, and the level of retrieved
information through the official sources was below 50% for 10 coun-
tries (Table 2).
3.3. NITAGs’ mandate and actual missions
Terms of reference, defining the official mandate of the NITAG,
were retrieved for a  narrow majority of countries (7 countries
out  of 13; Table 3). Terms of reference were stated in official
websites for Australia, Canada, Germany, Switzerland, and the UK
[10,12,14,19,20],  in a  decree for France [22] and in the charter
of Advisory Committee on Immunization Practices (ACIP) for the
US [23]. NITAGs’ functions were not  confined solely to the terms
of reference. Additional missions were identified, as specified in
Table 3, through official sources such as the German Standing Vac-
cination Committee’s (Ständigen Impfkommission; STIKO) Standard
Operating Procedure [24], the Joint Committee on Vaccination and
Immunization’s (JCVI) code of Practice for the UK [25], and through
literature review articles for France and Australia [26,27].
In sum, the main mission of all the selected NITAGs is to  provide
advice for NIP (Table 3). Other functions vary widely from one coun-
try to another, from conducting risk-benefit analysis for Germany
STIKO’s [24] and France’s Technical Vaccination Committee (Comité
technique des vaccinations; CTV) [22] to drawing recommenda-
tions for vaccines’ research and development for Switzerland’s The
Federal Vaccination Commission (Commission fédérale pour les vac-
cinations; CFV) [19] and Canada’s National Advisory Committee on
Immunization (NACI) [28] (Table 3).
3.4. Parent organizations and reporting line
NITAGs’ parent organizations are national health agencies,
councils or ministries for most countries, such as the High Coun-
cil for Public Health of France [13], the Superior Health Council of
Belgium [11], National Authority for Public Health of Hungary (pri-
mary research), the Department of Health and Ageing of Australia
[10], the Public Health Agency of Canada [12],  the National Board
of Health and Welfare of Sweden [18],  the Federal Office of Public
Health of Switzerland [19], the Health Council of the Netherlands
[16],  and the National Health System’s Inter-territorial Council of
Spain [29].  The Robert Koch Institute (RKI) provides all administra-
tive support to the STIKO [14],  and the ACIP hold its meetings at the
Centers for Disease Control and Prevention (CDC) [21].
Even if parent organizations vary from one country to  another,
NITAGs’ recommendations ultimately reached policy decision mak-
ers. Indeed, JVCI advises the Secretary of State for Health, Welsh
Ministers but also the Scottish and Northern Irish ministers [20,25],
the Australian Technical Advisory Group on Immunization (ATAGI)
provides advices to the Minister for Health and Ageing [10],  the
NACI reports to the Chief Public Health Officer of Canada [12],  the
CFV advises the Federal Department of Home Affairs and the Federal
Office of Public Health [19], the ACIP reports to the Secretary and the
assistant Secretary for Health and the CDC Director [23] and STIKO
recommendations are forwarded to the Health authorities and the
office of the Federal Joint Committee after the RKI’s decision [14]. Ta
b
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Table 4
Composition of NITAGS and members’ profile.
Members Core members’ Profiles
Core members* Stakeholders Composition Snapshot of 2011
Committee+
European countries
Belgium 29‡ 3‡ Members are affiliated to a  Belgian University and are
selected based on  their experience and knowledge in the
field of vaccines
n/a
France 17 [22] 9  [22] Specialists in infectious disease; pediatricians;
microbiologists; specialists in epidemiology and public
health; general practitioners; immunologist;
geriatrician; gynecologist-obstetrician/midwife;
internist; workplace physician; health economist;
sociologist [22]
8 MDpˆ4 Public health
specialistspˆ3  Biologistspˆ1
Health economistpˆ1
sociologist [22]
Germany 12–18 [14] n/a¥ Experts from different scientific disciplines of science
and in the field of public health as well as medical
professionals, who have extensive, practical experience
on  vaccination [14]
8 MDpˆ5 Public health
specialistspˆ4  Biologists
[14]
Hungary 12‡ 0‡ Members are OEK employees who are experts in
infectiology and virology
n/a
Italy  24‡ 0‡ n/a n/a
The  Netherlands 13‡ 3‡ Members have different backgrounds such as:
pediatricians, immunologists, epidemiologists,
Health-economists, microbiologist, public health
physicians, general practitioner, internal medicine,
virologists, occupational health physician, ethicist
n/a
Spain 19‡ 5‡ n/a n/a
Sweden¤ 0‡ 18‡ Employees from the  National Board of Health and
Welfare, expert from outside the board as well as
relevant people from other public agencies
n/a
Switzerland 16 [31] 4‡ All  Members are from the medical field and have
expertise in all  areas of immunization. Members are
chosen for their expertise and taking into account a
balanced gender distribution and regions [19]
7 MDpˆ7 Public health
specialistspˆ2  Biologists
[31]
UK# 18 [20] n/a Membership is determined on suitability for the role.
Members bring relevant knowledge, skills and
experience to the committee [25]
8 MDpˆ4 Public health
specialistspˆ2  Biologistspˆ1
Health economistpˆ2
Nursespˆ1 Ethicist [20]
Non-European countries
Australia 11 [10] n/a Technical experts, general practitioners and a consumer
[10]
6 MDpˆ2 Public health
specialistspˆ1  Biologistspˆ1
Nursepˆ1  Consumer
representativepˆ[10]
Canada 13 (in general 12)
[12]
17** [12] Recognized experts in the fields of pediatrics, infectious
diseases, immunology, medical microbiology, internal
medicine, nursing, pharmacy and public health [28]
n/a
US  14 [21] 34++ [30] Experts in infectious diseases, pediatrics, internal
medicine, family medicine, virology, immunology, public
health, preventive medicine, vaccine research and policy,
economics and cost-effectiveness, plus a  consumer
representative [30]
12 MDpˆ1 Public Health
Expertpˆ1 Consumer
representative [21]
* Voting members except for Hungary and Spain as the Spanish committee decides by consensus [3], and voting is not applicable for the  Hungarian committee as it is a
decision-support body (primary research).
+ Nearest year.
‡ Data retrieved from  Immunization Advisory Committees (2008) [3].
¥ In Germany representatives of the RKI, the Ministry of Health, the Federal States, the national regulatory authority (Paul-Ehrlich-Institute), the Federal Centre for Health
Education, the Joint Federal Committee, the Ministry of Foreign Affairs, and the Federal Armed Forces participate in the meetings without voting right [14].
¤ The National Board of Health and Welfare in Sweden does not operate with a  vaccine committee as such. ‘Vaccine committees’ are not fixed group/committees, but
committees are founded on  an  ad-hoc basis (according to disease focus, e.g. HPV, hepatitis etc.).
§ As per primary research.
# The Committee consists of such number of members as the  Secretary of State for Health and Welsh Ministers determine. Observers from the UK Govern-
ments/Administrations (i.e. officials from the Devolved Administrations) attend JCVI meetings and receive committee papers. Scottish and Northern Ireland observers
may  as well attend.
** 10 liaison members and 7 ex officio.
++ 26 liaison members and 8 ex officio.
3.5. NITAGs’ profile of members
Most committees were composed of core members, defined as
voting members, except for Spain and Hungary, and stakeholders
which can be either ex officio or  liaison members (Table 4). The
total number of NITAGs’ members varied greatly from one coun-
try to another and ranged from 48 in  the US to  12 in  Hungary. All
NITAGs, with the exception of Australia and Hungary, had more
than 15 members in  2011 and 6 NITAGs out of 13 had more than
20 members (Table 4).
The number and function of members were clearly defined
only for the ACIP and the CTV. Indeed, ACIP exact composition was
defined in official sources [21],  with the committee having to be
composed of 15 voting members, 8 ex  officio members(defined
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as representing other federal agencies with responsibility for
immunization programs)and 26 liaison members (defined as
representatives of liaison organizations). For  France, the CTV
decree fixed the number and profiles of voting members [22].
However, NITAGs’ compositions and members’ profiles were not
as clearly defined in the other NITAGs. Core members’ profiles
differed from one NITAG to another and could even differ from
one mandate to another for the same NITAG due to a  lack of
requirements for members’ profiles (Table 4). For example, STIKO
core members’ number could vary between 12 and 18, with
members defined roughly as experts from different disciplines
such as science, public health, medical science with extensive and
practical experience of vaccinations [14]. However, even though
NITAGs’ composition differed greatly, medical doctors represented
the highest proportion of member specialists in 2011, followed by
public health specialists, and biologists (Table 4).
Sub-committees, also called working groups, aiming to  review
available data on specific topics on vaccine and develop back-
grounds for development of recommendations, were identified in
all selected countries except Hungary, Italy, the Netherlands, Spain
and Sweden [11,24–28,30,31]. Sub-committees could be  composed
by committee members and experts outside the NITAGs’ members
and may  or may  not be permanent [25,30].
3.6. NITAGs’ appointment process
Committee members are appointed by  representatives of Health
Ministries or agencies for 6 NITAGs (Australia, Canada, France,
Germany, Sweden and the US) [14,22,23,27,28].  In the UK, while
the power to appoint JCVI members is held by  Welsh Ministers
and the Secretary of State for Health, the latter has delegated his
appointment functions to the Appointments Commission which
makes appointments on merit, usually after advertising each
vacancy and specifying the qualities required [25].  Committee
members are appointed by the department of home affairs in
Switzerland [19] and by the chairman of the Health Council in the
Netherlands.
Duration of members’ appointment was 4 years in Australia,
Canada, France, Switzerland, the Netherlands, the UK and the
US [19,22,23,25,27,28] and 3 years in Germany [14].  There is
no fixed duration of appointment for committee members in
Sweden, and mandated duration was not specified for Hungary
(primary research). Data was not available for Belgium, Spain and
Italy.
Core members are remunerated in Australia, Belgium, the
Netherlands and the US [21,23,32] but not in France, Germany,
Sweden, Switzerland, and the UK [14,24–26]. Committee members
declare conflict of interest in  the majority of the selected countries:
Australia, Belgium, Canada, France, Germany, the Netherlands,
Sweden, Switzerland, the UK, and the US [13,14,19–21,27,28].  Usu-
ally, the declarations are available on NITAGs webpages [13,19–21].
Conflict of interest declarations are not required in  Hungary
(primary research), and data were not available for Italy and
Spain.
3.7. Recommendation-making: Decision analysis framework and
meeting process
Germany and the US use a  detailed and standardized methodol-
ogy for reliable, robust and reproducible assessments: the Grades
of Recommendation, Assessment, Development and Evaluation
(GRADE) [14,21,24,30].  Canada, Italy, Spain and Switzerland’s Com-
mittees do not use tools as robust and reliable as GRADE but list
clearly their decision-making criteria [29,33–35] (Table 5). France,
Sweden and the UK state some of the decision-making criteria
without defining a clear decision analysis framework [18,25,26] Ta
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Table 6
Access to information related to  NITAG activities.
Meetings open to
public
Published meeting
agenda
Published meeting
minutes
Published NITAG
advices
Published evaluation
reports
Yes US [21] UK [20,25];  US  [21] AU [10]; UK [20];  US
[21]
AU [27];  BE [11];  CA
[28]; CH [31]; DE [24];
ES [17]; FR [26];  HU*;
NL*; SE*; UK [25];  US
[21,30]
AU [27]; BE [11]; CA
[28];  CH [31];  DE [24];
ES [17];  FR  [26]; HU*;
NL [16]; UK [25];  US
[30]
No BE*; CA [28]; CH [31];
DE [24];  FR [26];  HU*;
NL*;  SE*;  UK [25]
AU [10]; BE*;  CA [12];
DE [24]; FR  [26];  HU*;
NL*; SE*
BE*;  CA [28]; CH [31];
DE [24];  FR  [26]; HU*;
NL*; SE*
Not found IT; ES; AU CH;  IT;  ES; ES; IT IT SE; IT
AU: Australia, BE: Belgium, CA: Canada, CH: Switzerland, FR: France, DE: Germany; HU: Hungary, IT: Italy, NL: the Netherlands, ES: Spain, SE: Sweden, UK: the  United
Kingdom, US: the United States.
* As per primary research.
(Table 5). Decision-making criteria were not found for Australia,
Belgium and Hungary, and official NITAGs’ time to  advice after
regulatory approval was not retrieved for all selected countries.
Advices are publicly available in all selected countries except
Italy, where only the national plan of immunization was  retrieved
[11,24–28,30,31] (Table 6). Only Australia, the UK, and the US pub-
lished meeting minutes [10,20,21],  and meetings were open to
public only in the US [21] (Table 6).
3.8. Comments and outcomes of the expert panel
Experts validated the findings of the research and acknowledged
that vaccines needed a country-specific and distinct decision-
making paths compared to other drugs. The panel provided detailed
perspectives on Spain and Italy. Specifically, experts pinpointed
that, public health decision-making is  decentralized in  the two
countries. Thus, vaccine assessment and recommendation are
handled mainly at regional level, making it difficult to  retrieve
information at the national level.
Experts highlighted the fact that decision-making processes for
vaccines were not  always as structured and transparent as pro-
cesses for other medicines, thus leaving room for higher political
influence. The panel underlined the importance of vaccines from a
public health perspective and regretted the scarcity of public infor-
mation about NITAGs and their processes. Indeed experts’ broad
opinion is that NITAG appraisals should be  better reported to the
general public and the overall information about vaccines should
be enhanced. There is  a need to  provide more information to the
public and health councils on reasons for no recommendation (e.g.
lack of data, lack of budget, etc.) in order not to  jeopardize trust in
vaccines.
Finally, experts’ opinion was that NITAGs’ recommendations
should not only be restricted to  vaccine of the NIP, fully funded by
the  public health system, but also concern other vaccines, thereby
allowing individuals’ access to vaccines with partial or full out-of-
pocket payment, as in  Switzerland.
4. Discussion
The aim of  this project was to compare and analyze NITAG
bodies and working processes of 13 developed countries. This com-
parison aimed to cover all aspects of NITAGs’ policies. However,
a number of limitations should be considered when interpreting
the results of the study due to  the lack of data. Indeed, complete
information was not always retrieved despite using three sources,
and few NITAG specific publications were available. Furthermore,
no direct contact could be  established for Italy and Spain, for which
with amount of available information via official sources and
articles was quite low, leaving a  gap in retrieved data. And finally,
the study was limited to the formalized process, either published
in literature or  websites, which, not being systematically updated,
might not reflect the actual NITAG’s functioning.
Over 80% of the information was retrieved for 9 out of 13  coun-
tries, allowing for a  robust analysis of the data (Table 2). The level
of publicly available information varied highly from one country
to  another. Data about NITAGs’ body and processes was clear and
readily available for a  few countries, such as Germany, the UK  and
the US and scarce and incomplete for several other countries such
as Hungary, Spain and Italy (Table 2).
None of the selected NITAGs covered the recommended man-
date as defined by Duclos et al. [6] (Table 3), and the terms of
reference did not cover all actual roles of NITAGs, suggesting that
terms of references needed to  be updated and new functions of
NITAGs fully acknowledged.
Committee members’ number and profiles were not clearly
stated in most countries, with committees’ body varying between
countries and years. Only 6 NITAGs had between 10 and 16  core
members as recommended by Duclos et al. [6].  The number of  core
members exceeded 16 in  6 countries, suggesting the need for a
very accurate and effective decision analysis framework to ensure
a  good process with reliable and reproducible recommendations
(Table 4). And while Duclos et al. [6] recommended that members
be  remunerated in order to avoid them giving low priority to  their
NITAG roles, only 4 NITAGs remunerated their members.
Decision analysis frameworks were only available in 10 out
of the 13 selected countries (Table 5). These frameworks using
decision criteria are critical for a  transparent, structured, repro-
ducible and reliable decision-making [8],  as they help increase
trustworthiness in introducing new vaccines in the NIP, as well
as in  promoting public confidence [36]. Lack of standardization in
vaccine evaluation was identified as cause of heterogeneity and
inequity of immunization programs [34].  Nevertheless, the use of
efficient decision-making tools, such as GRADE, has been devel-
oping and is expected to  expand to more countries in the coming
years.
This study also illustrated the very restricted access to  impor-
tant information such as agenda, meeting minutes and full reports.
With NITAGs recommendations being ultimately used by policy
decision makers for implementation and funding of NIPs, guidances
should be well-informed and transparent. Moreover, open data
and solid decision-making process are critical for NIP’s reliability
among the public and health care professionals. Indeed, while lack
of access to  decision-making processes can have a negative impact
on the vaccination’s perceived value, understanding of  vaccination
recommendations, implementation and funding processes, may
reduce time-to-access for new vaccines [37].
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Finally, although the specific characteristics of vaccines need to
be acknowledged in determining the evaluation process, the deci-
sion processes would benefit from studying the progress of HTA
agencies in general over the last 10 years, especially relating to the
analytical decision framework, the time to issuing advice, and the
practice of publishing appraisals.
5. Conclusion
This study supports previous findings about the heterogeneity
of NITAGs processes, potentially explain the disparity in access to
vaccinations and immunization programs across Europe [37,38].
Clearly defined terms of reference that reflect the roles and mis-
sions, structured decision analysis framework for the evaluation of
the vaccines, together with initiatives such as the VENICE II  project
[7] that provide access to information and reports, are  therefore
needed to support the development of best practices among the
NITAGs and enhance reliability of NIP.
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Global Health
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and AB innoculat*
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